Replies to post #4905 on Momenta Pharmaceuticals, Inc. (MNTA)

[oc631]

• A buyout offer.
IMHO - Very Unlikely. They have never ever mentioned in the 20 or so conf calls in past 12 months that they are exploring or are interested in an all out acquisition.
However this wouldn't preclude another company to make an unsolicited bid that the board would have to evaluate. I gave the example of TEVA (which has immediate upside if it were to acquire MNTA at even twice of today's price. IMHO, board would have to agree to such a price. one can argue all day long about FOB potential-lets face it, it is at least 4-5 years away, and the company has admitted that it is still in initial "research" stage. And who knows what clinical trials are needed for interchangeability)

A buyout by Teva certainly would be viewed as being anti-competitive and would be challenged by the Justice Department. We've been over this before. What has changed is the buying power of Sandoz/NVS considering the strength of the Swiss Franc and the drop in MNTA's share price. Having a strong currency isn't all bad and we understand the synergies between companies.